

Serge Cremers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5650370/publications.pdf>

Version: 2024-02-01

186
papers

7,169
citations

71102

41
h-index

69250

77
g-index

191
all docs

191
docs citations

191
times ranked

12056
citing authors

#	ARTICLE	IF	CITATIONS
1	CARE guidelines for case reports: explanation and elaboration document. <i>Journal of Clinical Epidemiology</i> , 2017, 89, 218-235.	5.0	993
2	Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. <i>BMC Medicine</i> , 2016, 14, 10.	5.5	384
3	Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950 "Metabolites in Frozen Human Plasma. <i>Journal of Lipid Research</i> , 2017, 58, 2275-2288.	4.2	312
4	Chloroquine and hydroxychloroquine in covid-19. <i>BMJ, The</i> , 2020, 369, m1432.	6.0	297
5	Multivalent Small-Molecule Pan-RAS Inhibitors. <i>Cell</i> , 2017, 168, 878-889.e29.	28.9	213
6	The Need for Randomization in Animal Trials: An Overview of Systematic Reviews. <i>PLoS ONE</i> , 2014, 9, e98856.	2.5	199
7	Biomarkers "A General Review. <i>Current Protocols in Pharmacology</i> , 2017, 76, 9.23.1-9.23.17.	4.0	196
8	Overdiagnosis: what it is and what it isn't. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 1-3.	3.5	191
9	Pharmacology of bisphosphonates. <i>Bone</i> , 2011, 49, 42-49.	2.9	176
10	Defining "nutraceuticals": neither nutritious nor pharmaceutical. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 8-19.	2.4	158
11	Vitamin D Storage in Adipose Tissue of Obese and Normal Weight Women. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 237-242.	2.8	138
12	Pharmacology of bisphosphonates. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1052-1062.	2.4	132
13	Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. <i>BMC Medicine</i> , 2016, 14, 191.	5.5	113
14	A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. <i>Blood</i> , 2018, 131, 397-407.	1.4	109
15	Quantitative Evaluation of Collagen Crosslinks and Corresponding Tensile Mechanical Properties in Mouse Cervical Tissue during Normal Pregnancy. <i>PLoS ONE</i> , 2014, 9, e112391.	2.5	102
16	Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2742-2750.	3.6	101
17	Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. <i>BMJ: British Medical Journal</i> , 2018, 363, k4666.	2.3	91
18	Remdesivir in covid-19. <i>BMJ, The</i> , 2020, 369, m1610.	6.0	91

#	ARTICLE	IF	CITATIONS
19	Redefining rapid reviews: a flexible framework for restricted systematic reviews. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 201-203.	3.5	90
20	Drugs and the renin-angiotensin system in covid-19. <i>BMJ, The</i> , 2020, 369, m1313.	6.0	89
21	Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. <i>BMJ, The</i> , 2021, 374, n1537.	6.0	88
22	Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. <i>Critical Reviews in Toxicology</i> , 2016, 46, 477-489.	3.9	86
23	Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 249-256.	2.4	82
24	Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 4663-4675.	7.0	80
25	Overtesting and undertesting in primary care: a systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e018557.	1.9	80
26	Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease. <i>Drugs</i> , 2006, 66, 2031-2058.	10.9	76
27	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 225-245.	9.4	74
28	Comparison of essential medicines lists in 137 countries. <i>Bulletin of the World Health Organization</i> , 2019, 97, 394-404C.	3.3	67
29	A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. <i>European Journal of Clinical Pharmacology</i> , 2002, 57, 883-890.	1.9	66
30	Reduced Salt Intake for Heart Failure. <i>JAMA Internal Medicine</i> , 2018, 178, 1693.	5.1	65
31	Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process. <i>BMJ Open</i> , 2017, 7, e017125.	1.9	64
32	Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. <i>Cancer Causes and Control</i> , 2015, 26, 187-203.	1.8	60
33	Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. <i>Clinical Cancer Research</i> , 2019, 25, 5271-5283.	7.0	59
34	Poor medication adherence in clinical trials: consequences and solutions. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 149-150.	46.4	58
35	Unlicensed and off-label uses of medicines: definitions and clarification of terminology. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2615-2625.	2.4	55
36	Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 386-389.	2.4	49

#	ARTICLE	IF	CITATIONS
37	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 2096-2106.	7.0	48
38	A systematic evaluation of collagen cross-links in the human cervix. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 321.e1-321.e8.	1.3	47
39	Medical Devices: Definition, Classification, and Regulatory Implications. <i>Drug Safety</i> , 2020, 43, 83-93.	3.2	47
40	Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. <i>Contraception</i> , 2017, 95, 464-469.	1.5	45
41	Transvaginal mesh failure: lessons for regulation of implantable devices. <i>BMJ: British Medical Journal</i> , 2017, 359, j5515.	2.3	45
42	Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	43
43	A manifesto for clinical pharmacology from principles to practice. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 3-13.	2.4	41
44	Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 4097-4109.	7.0	41
45	Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease. <i>Human Molecular Genetics</i> , 2018, 27, 1545-1555.	2.9	38
46	Palmitic Acid Reduces Circulating Bone Formation Markers in Obese Animals and Impairs Osteoblast Activity via C16-Ceramide Accumulation. <i>Calcified Tissue International</i> , 2016, 98, 511-519.	3.1	37
47	Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2114-2122.	2.4	37
48	Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. <i>Pharmacotherapy</i> , 2018, 38, 730-738.	2.6	36
49	Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism – translating the pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 252-267.	2.4	35
50	Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4208-4214.	3.6	33
51	Summarising good practice guidelines for data extraction for systematic reviews and meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 88-90.	3.5	33
52	First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma. <i>Oncologist</i> , 2021, 26, 184-e366.	3.7	32
53	Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity. <i>Diabetes</i> , 2015, 64, 3396-3405.	0.6	31
54	Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 112, 114-122.	1.9	31

#	ARTICLE	IF	CITATIONS
55	Balanced prescribing – principles and challenges. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 566-572.	2.4	29
56	Therapeutic drug monitoring in the era of precision medicine: opportunities!. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 900-902.	2.4	29
57	Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 646-667.	2.4	28
58	Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year. <i>Contraception</i> , 2016, 93, 263-265.	1.5	26
59	Targeted inhibition of glutaminase as a potential new approach for the treatment of <i>NF1</i> associated soft tissue malignancies. <i>Oncotarget</i> , 2017, 8, 94054-94068.	1.8	26
60	Evidence of Misclassification of Drug–Event Associations Classified as Gold Standard –Negative Controls™ by the Observational Medical Outcomes Partnership (OMOP). <i>Drug Safety</i> , 2016, 39, 421-432.	3.2	25
61	Factors associated with the prescribing of high-dose opioids in primary care: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2020, 18, 68.	5.5	25
62	Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. <i>Blood Advances</i> , 2018, 2, 969-978.	5.2	24
63	Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. <i>Annals of the New York Academy of Sciences</i> , 2011, 1218, 80-87.	3.8	23
64	Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib. <i>Clinical Cancer Research</i> , 2017, 23, 3084-3096.	7.0	23
65	The use of mechanistic evidence in drug approval. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 1166-1176.	1.8	23
66	Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories. <i>British Journal of Pain</i> , 2022, 16, 34-40.	1.5	22
67	Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 52-55.	2.4	21
68	Drugs for rare disorders. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1607-1613.	2.4	21
69	Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015/16. <i>BMC Medicine</i> , 2018, 16, 229.	5.5	21
70	Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems. <i>Therapie</i> , 2017, 72, 555-561.	1.0	20
71	The law of mass action and the pharmacological concentration–effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 56-61.	2.4	19
72	Journal Clubs: 2. Why and how to run them and how to publish them. <i>Evidence-Based Medicine</i> , 2017, 22, 232-234.	0.6	18

#	ARTICLE	IF	CITATIONS
73	Sclerostin measurement in human disease: Validity and current limitations. <i>Bone</i> , 2017, 96, 24-28.	2.9	18
74	Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 63-72.	2.4	18
75	Aspiration of conjugated bile acids predicts adverse lung transplant outcomes and correlates with airway lipid and cytokine dysregulation. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 998-1008.	0.6	18
76	Relation between opioid consumption and inclusion of opioids in 137 national essential medicines lists. <i>BMJ Global Health</i> , 2020, 5, e003563.	4.7	18
77	A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3K β Inhibitor, in Patients with Metastatic Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5504.	3.7	18
78	Deaths attributed to the use of medications purchased online. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 60-64.	3.5	18
79	The toxicological significance of post-mortem drug concentrations in bile. <i>Clinical Toxicology</i> , 2018, 56, 7-14.	1.9	17
80	Spotlight Commentary: Model-informed precision dosing must demonstrate improved patient outcomes. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2238-2240.	2.4	17
81	Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations. <i>Drug Safety</i> , 2022, 45, 407-418.	3.2	17
82	Endogenous thrombin potential changes during the first cycle of oral contraceptive use. <i>Contraception</i> , 2017, 95, 456-463.	1.5	16
83	Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5 α -reductase Inhibition. <i>European Urology</i> , 2017, 72, 499-506.	1.9	16
84	Maternal serum cytokine levels and risk of bipolar disorder. <i>Brain, Behavior, and Immunity</i> , 2017, 63, 108-114.	4.1	16
85	Drug and therapeutics committees as guardians of safe and rational medicines use. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 10-12.	2.4	16
86	Clotting factor changes during the first cycle of oral contraceptive use. <i>Contraception</i> , 2016, 93, 70-76.	1.5	15
87	A word about evidence: "rapid reviews" or "restricted reviews"? <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 204-205.	3.5	15
88	On the pharmacological evaluation of bisphosphonates in humans. <i>Bone</i> , 2020, 139, 115501.	2.9	15
89	Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names. <i>PLoS ONE</i> , 2015, 10, e0145431.	2.5	15
90	Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity. <i>Drug Safety</i> , 2022, 45, 137-144.	3.2	15

#	ARTICLE	IF	CITATIONS
91	Medical eponyms: taxonomies, natural history, and the evidence. <i>BMJ, The</i> , 2014, 349, g7586-g7586.	6.0	14
92	Medication errors detected in non-traditional databases: types of errors in methotrexate dosing as listed in four different Danish registers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1375-1379.	1.9	14
93	Impaired postprandial lipemic response in chronic kidney disease. <i>Kidney International</i> , 2016, 90, 172-180.	5.2	14
94	Inhibiting the proton pump: mechanisms, benefits, harms, and questions. <i>BMC Medicine</i> , 2016, 14, 172.	5.5	14
95	Estimating systemic exposure to levonorgestrel from an oral contraceptive. <i>Contraception</i> , 2017, 95, 398-404.	1.5	14
96	Sales of Over-the-Counter Products Containing Codeine in 31 Countries, 2013–2019: A Retrospective Observational Study. <i>Drug Safety</i> , 2022, 45, 237-247.	3.2	14
97	Pharmacometrics and systems pharmacology for metabolic bone diseases. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1136-1146.	2.4	13
98	COVID-19 vaccines: the importance of transparency and fact-based education. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2107-2110.	2.4	13
99	Coroners' concerns to prevent harms: a series of coroners' case reports to serve patient safety and educate the public, clinicians and policy-makers. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 37-38.	3.5	13
100	Variation in diagnostic test requests and outcomes: a preliminary metric for OpenPathology.net. <i>Scientific Reports</i> , 2018, 8, 4752.	3.3	12
101	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e030596.	1.9	12
102	Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. <i>Pituitary</i> , 2021, 24, 170-183.	2.9	12
103	How similar are biosimilars?. <i>BMJ, The</i> , 2016, 353, i2721.	6.0	11
104	Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners' case reports. <i>BJGP Open</i> , 2022, 6, BJGPO.2021.0150.	1.8	11
105	What is a "complex systematic review"? Criteria, definition, and examples. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 127-130.	3.5	10
106	Prescribing biosimilars. <i>BMJ: British Medical Journal</i> , 2018, 362, k3141.	2.3	10
107	Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 112-113.	3.5	10
108	Serum glutamine and hospital-acquired infections after aneurysmal subarachnoid hemorrhage. <i>Neurology</i> , 2018, 91, e421-e426.	1.1	9

#	ARTICLE	IF	CITATIONS
109	Arsenic exposure associated T cell proliferation, smoking, and vitamin D in Bangladeshi men and women. PLoS ONE, 2020, 15, e0234965.	2.5	9
110	Estimating systemic exposure to ethinyl estradiol from an oral contraceptive. American Journal of Obstetrics and Gynecology, 2015, 212, 614.e1-614.e7.	1.3	8
111	Oral hormone pregnancy tests and the risks of congenital malformations: a systematic review and meta-analysis. F1000Research, 2018, 7, 1725.	1.6	8
112	The use of mechanistic reasoning in assessing coronavirus interventions. Journal of Evaluation in Clinical Practice, 2021, 27, 684-693.	1.8	8
113	The Oxford Catalogue of Opioids: A systematic synthesis of opioid drug names and their pharmacology. British Journal of Clinical Pharmacology, 2021, 87, 3790-3812.	2.4	8
114	When I use a word Listening to the patient. BMJ, The, 2022, 376, o646.	6.0	8
115	Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification. Drug Safety, 2017, 40, 431-441.	3.2	7
116	Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980). British Journal of Clinical Pharmacology, 2018, 84, 1668-1685.	2.4	7
117	Drugs for the treatment of metabolic bone diseases. British Journal of Clinical Pharmacology, 2019, 85, 1049-1051.	2.4	7
118	Withdrawn medicines included in the essential medicines lists of 136 countries. PLoS ONE, 2019, 14, e0225429.	2.5	7
119	Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers) variants in the spellings of drug names in PubMed: a database review. BMJ, The, 2016, 355, i4854.	6.0	6
120	Journal Clubs: 1. Origins. Evidence-Based Medicine, 2017, 22, 231-231.	0.6	6
121	Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin. Statistical Methods in Medical Research, 2018, 27, 564-578.	1.5	6
122	Lorcaserin in obesity: minimal benefits and ill-defined harms. BMJ Evidence-Based Medicine, 2019, 24, 145-146.	3.5	6
123	Why reports of clinical trials should include updated meta-analyses. BMJ Evidence-Based Medicine, 2020, 25, 1-2.	3.5	6
124	Bone markers--new aspects. Clinical Laboratory, 2008, 54, 461-71.	0.5	6
125	Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. Endocrine, 2015, 50, 504-507.	2.3	5
126	Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. Aids, 2018, 32, 2517-2524.	2.2	5

#	ARTICLE	IF	CITATIONS
127	Examining the “psychopharmacology revolution” (1950–1980) through the advertising of psychoactive drugs in the <i>British Medical Journal</i> . <i>Journal of Psychopharmacology</i> , 2018, 32, 1056-1066.	4.0	5
128	When I use a word The Precautionary Principle: a brief history. <i>BMJ, The</i> , 2021, 375, n3059.	6.0	5
129	A UPLC–MS/MS method for the quantitation of Ulipristal acetate in human serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1059, 43-48.	2.3	4
130	Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis. <i>Obesity</i> , 2018, 26, 513-521.	3.0	4
131	Combining and converting groups when extracting data for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 85-87.	3.5	4
132	Nonmedical use of prescription drugs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1635-1636.	2.4	4
133	Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 399-409.	3.1	3
134	The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the <i>British Medical Journal</i> from 1955/6 to 1985/6. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1901-1906.	2.4	3
135	A tetrahydrobiopterin deficit finding in schizophrenia: A confirmation study. <i>Schizophrenia Research</i> , 2019, 210, 316-318.	2.0	3
136	Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 127-129.	3.5	3
137	Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature. <i>Systematic Reviews</i> , 2020, 9, 180.	5.3	3
138	On precision dosing of oral small molecule drugs in oncology. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 263-270.	2.4	3
139	Dealing with categorical risk data when extracting data for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 43-45.	3.5	3
140	When I use a word No jab, no job? A benefit:harm balance analysis. <i>BMJ, The</i> , 2021, 375, n2934.	6.0	3
141	When I use a word Medical anniversaries in 2022. <i>BMJ, The</i> , 2022, 376, o39.	6.0	3
142	Lessons from working across fields to develop a framework for informed choices. <i>Research for All</i> , 2022, 6, .	0.4	3
143	When I use a word The Precautionary Principle: a definition. <i>BMJ, The</i> , 2021, 375, n3111.	6.0	3
144	When I use a word Memory, semantic and episodic. <i>BMJ, The</i> , 2022, 376, o804.	6.0	3

#	ARTICLE	IF	CITATIONS
145	Challenged comparison of tacrolimus assays. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 246-250.	1.2	3
146	Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis. Pharmacoepidemiology and Drug Safety, 2017, 26, 1328-1337.	1.9	2
147	Non-existent authors. BMJ: British Medical Journal, 2017, 359, j5706.	2.3	2
148	Bone turnover markers in women participating in a dose-finding trial of a contraceptive vaginal ring releasing Nestorone and estradiol. Contraception, 2019, 99, 329-334.	1.5	2
149	Harms and the Xmas factor. BMJ, The, 2020, 371, m4067.	6.0	2
150	Extracting data from diagnostic test accuracy studies for meta-analysis. BMJ Evidence-Based Medicine, 2021, 26, 19-21.	3.5	2
151	Insulin Sensitivity After Living Donor Nephrectomy. Transplantation Proceedings, 2021, 53, 1858-1864.	0.6	2
152	Sustainable medicines development and use: Our collective responsibility for action to mitigate the natural world crisis. British Journal of Clinical Pharmacology, 2022, 88, 3013-3015.	2.4	2
153	When I use a word . . . Taking therapeutic care. BMJ, The, 2021, 375, n3010.	6.0	2
154	When I use a word . . . New medical words 1422â€“1972. BMJ, The, 2022, 376, o187.	6.0	2
155	When I use a word . . . Medical words newly logged in the OED in September 2021. BMJ, The, 2022, 376, o255.	6.0	2
156	When I use a word . . . Diagnosis. BMJ, The, 2022, 376, o747.	6.0	2
157	Placeboâ€™s invisible brother: a restricted scoping review of biomedical literature on the nocebo effect. Pain, 2022, Publish Ahead of Print, .	4.2	2
158	Clinical and translational pharmacology of bisphosphonates. , 2020, , 1671-1687.		1
159	Was William Harveyâ€™s commitment to experimentation reflected in his clinical practice?. Journal of the Royal Society of Medicine, 2021, 114, 313-322.	2.0	1
160	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. Programme Grants for Applied Research, 2021, 9, 1-218.	1.0	1
161	Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate.. Blood, 2012, 120, 2758-2758.	1.4	1
162	How a VOICE for clinical pharmacology turns into a RECIPE for its development. Translational and Clinical Pharmacology, 2016, 24, 1.	0.9	1

#	ARTICLE	IF	CITATIONS
163	A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2020, 133, 351-359.	1.6	1
164	When I use a word The efficiency paradox. <i>BMJ, The</i> , 2021, 375, n2712.	6.0	1
165	Ethics in clinical pharmacology: Facilitating public trust. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5-6.	2.4	1
166	When I use a word Lexicographical anniversaries. <i>BMJ, The</i> , 2022, 376, o105.	6.0	1
167	When I use a word St Bartholomewâ€™onomastics and reputation. <i>BMJ, The</i> , 2022, 376, o370.	6.0	1
168	When I use a word Medical patronymics, metronymics, and papponymics. <i>BMJ, The</i> , 2022, 376, o437.	6.0	1
169	When I use a word Remembrance of things past. <i>BMJ, The</i> , 2022, 377, o873.	6.0	1
170	When I use a word Medical magic. <i>BMJ, The</i> , 2022, 377, o1092.	6.0	1
171	A phase Ia/Ib study of intrathecal deferoxamine in patients with leptomeningeal metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2074-TPS2074.	1.6	1
172	Adverse events in patients taking cephalosporins versus placebo for any indication. <i>The Cochrane Library</i> , O, , .	2.8	0
173	NuleĀ~ntĀm Ā~li PaĀ~kw. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 8-9.	2.4	0
174	Was this Thomas Willisâ€™s greatest clinical success?. <i>Brain</i> , 2021, 144, e56-e56.	7.6	0
175	Introduction to clinical pharmacology at large. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3026-3027.	2.4	0
176	Concise advice: Introducing a new clinically focused BJCP series on evidenceâ€based (de)prescribing in challenging situations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4484-4487.	2.4	0
177	A basal gene expression signature to predict for synergy of combined EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7546-7546.	1.6	0
178	When I use a word Nasty medical eponyms. <i>BMJ, The</i> , 2021, 375, n2777.	6.0	0
179	When I use a word Examining the efficiency paradox. <i>BMJ, The</i> , 2021, 375, n2856.	6.0	0
180	When I use a word Vaccinationâ€™rights and duties. <i>BMJ, The</i> , 2022, 376, o317.	6.0	0

#	ARTICLE	IF	CITATIONS
181	When I use a word Medical trigger warnings. BMJ, The, 2022, 376, o579.	6.0	0
182	When I use a word Bioscience journalsâ€™an open and shut case?. BMJ, The, 2022, 376, o536.	6.0	0
183	When I use a word Medical aphorisms. BMJ, The, 2022, 377, o934.	6.0	0
184	When I use a word Medical hyacinths. BMJ, The, 2022, 377, o1036.	6.0	0
185	When I use a word More medical magic. BMJ, The, 2022, 377, o1154.	6.0	0
186	When I use a word Some words about the climate. BMJ, The, 2022, 377, o1222.	6.0	0